UNSPSC 51371801: Promedol or trimeperidine

This classification denotes an opioid receptor agonist with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1M2IB31DTS, chemically known as 1,2,5-trimethyl-4-phenyl-4-propionyloxypiperidine but generally known as promedol, which bears US NIH Compound Identifier 6148. European Medicines Agency schedules Trimeperidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11303MIG. The term PROMEDOL is an International Non-Proprietary Name.

Promedol or trimeperidine bears US NLM identifiers UMLS ID C0041029 and NCI Concept Code C76848. SMILES: CCC(=O)OC1(C[C@@H](N(C[C@H]1C)C)C)C2=CC=CC=C2.

UNSPSC 51371801 Promedol or trimeperidine is a Commodity code tracking pharmaceutical procurement by state and local agencies, though recent solicitation activity under this code shows minimal alignment with its nominal scope. The single recent opportunity in the dataset — Seminole County, Florida's IFB 60459723LAS — targets naloxone and drug deactivation systems rather than promedol or trimeperidine, indicating a tagging mismatch between the code and the actual goods being procured. State and local governments use this code tier to source controlled pharmaceuticals and related medical supplies, but the available record does not support characterization of typical issuing bodies, work patterns, or issuing-body frequency under the code's intended scope.

Seminole County, Florida posted the sole recent opportunity on June 30, 2026, with an IFB response deadline of July 26, 2023 (a date that predates the posting and appears inconsistent in the source record). The procurement sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carried a two-year initial term with a one-year renewal option and included E-Verify compliance, drug-free workplace certification, workers' compensation insurance, commercial general liability coverage, and a three-month probationary termination clause. No explicit set-aside designations were noted. Given the single, tangential opportunity and the code-scope mismatch, this Commodity code shows little current procurement activity relevant to its stated pharmaceutical classification.